A bitter pill to swallow: adjustments to oral contraceptive pill use in polycystic ovary syndrome.
Marco CalcagnoPietro SerraAndrea EtruscoChrysoula Margioula-SiarkouSanjia TerzicAndrea GianniniSimone GarzonFederico FerrariMiriam DellinoAntonio Simone LaganàPublished in: Expert opinion on pharmacotherapy (2024)
Considering the recent re-analysis of PCOS Rotterdam Criteria by the Expert Group on Inositol in Basic and Clinical Research, and on PCOS (EGOI-PCOS), the traditional Rotterdam phenotypes can be reclassified to achieve more efficacious therapy choices. Using personalized therapies that consider the specific clinical characteristics of the patient allows to improve the management of the syndrome, thus avoiding the generalized use of OCPs, which risk treating only symptoms of PCOS rather than the underlying cause. In cases when contraceptive purpose is desired, patients may benefit from combined therapy with diet or insulin-sensitizer agents, as inositol, to rebalance the metabolic profile, thus reducing the risk of developing future complications.
Keyphrases
- polycystic ovary syndrome
- insulin resistance
- end stage renal disease
- type diabetes
- ejection fraction
- newly diagnosed
- chronic kidney disease
- adipose tissue
- physical activity
- prognostic factors
- weight loss
- metabolic syndrome
- patient reported outcomes
- current status
- mesenchymal stem cells
- clinical practice
- chemotherapy induced